by David Brindley | Jan 16, 2013
claimtoken-510012802486f [pullquote]The cell therapy industry has an encyclopaedic void. But is this void one that needs addressing?”[/pullquote]This post was initially intended to be a short vignette (not so short, as it turns out) exploring whether or not the...
by Paul Krzyzanowski | Jan 8, 2013
This year, your household will pay $360 for the use of Intellectual Property (IP) held by people and corporations outside of Canada. For a little less than a dollar a day, you’re supporting industries like biotechnology, high-tech electronics, and engineering in other...
by Nick Dragojlovic | Dec 20, 2012
“Stem Cells Make Aging Mice Young Again” – ABC News “’Factor X’ — Have we finally found the fountain of youth?” – Fox News “Stem cells, the secret to eternal youth?” – Euronews.com Headlines like these are all too common and underscore how the news...
by David Brindley | Nov 30, 2012
The global health care sector is innovative, impactful and, despite addressing fundamental problems in human health, can be inescapably faddish. Despite the industry’s pride in an empirical approach that yields robust and practicable data, the covers of Nature,...
by Paul Krzyzanowski | Nov 21, 2012
While the 2012 US election was in full swing, I reminded readers that despite the dominance of the world’s economic problems in this cycle, stem cell research was a political issue that hadn’t completely gone away.[pullquote]Ironically, if – and this is a...
by Nick Dragojlovic | Nov 8, 2012
If you’ve been feeling like you can’t open a web browser these days without finding a story about induced pluripotent stem cells (iPSCs), you’re not alone. Unlike embryonic stem cells, iPSCs are created by directly reprogramming adult cells taken from donors or...
Comments